Ofatumumab for rituximab-resistant nephrotic syndrome

N Engl J Med. 2014 Mar 27;370(13):1268-70. doi: 10.1056/NEJMc1308488.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adolescent
  • Adrenal Cortex Hormones / therapeutic use
  • Albuminuria / urine
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Child
  • Child, Preschool
  • Cyclophosphamide / therapeutic use
  • Drug Resistance*
  • Female
  • Glomerular Filtration Rate
  • Humans
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / therapeutic use
  • Nephrotic Syndrome / drug therapy*
  • Nephrotic Syndrome / physiopathology
  • Nephrotic Syndrome / urine
  • Recurrence
  • Remission Induction
  • Rituximab
  • Tacrolimus / therapeutic use
  • Withholding Treatment

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
  • Cyclophosphamide
  • Mycophenolic Acid
  • ofatumumab
  • Tacrolimus